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Abstract
Introduction: The aim of this study was to determine whether girls with anorexia nervosa (AN) exhibited any relationships between 
serum levels of LP, ADIPO, RES, VISF, APE-36, APE-12, and bone markers, OPG and sRANKL.
Material and methods: Serum levels of selected adipose tissue hormones, OC, CTx, OPG and sRANKL were assessed using ELISA in 
86 study participants suffering from AN and 21 healthy controls, all aged 13 to 18 years. 
Results: Girls with AN showed a significant reduction in body mass, BMI, serum concentrations of LP, RES, VISF, APE-36, APE-12, OC, 
CTx and increased ADIPO concentration. These changes were associated with significant increases in OPG and sRANKL and a decrease 
in the OPG/sRANKL ratio. Significant positive correlations were revealed between BMI and LP, APE-36, CTx, OPG/sRANKL ratio; OC 
and VISF; OPG and ADIPO; OPG/sRANKL ratio and LP, APE-36, APE-12. Significant negative correlations were revealed between CTx, 
sRANKL and RES, APE-36; OPG and APE-36, APE-12; OPG/sRANKL ratio and ADIPO. VISF was shown to be an independent predictor 
of OC. APE-36 and RES turned out to be independent predictors of CTx, and sRANKL, APE-36 and ADIPO were independent predictors 
of OPG while APE-36, LP and ADIPO were independent predictors of the OPG/sRANKL ratio.
Conclusions: Changes in bone markers, OPG, sRANKL and/or the OPG/sRANKL ratio exhibited by girls with AN have been found to 
be associated with changes in the levels of the selected adipose tissue hormones. Abnormal relationships between bone metabolism and 
LP, ADIPO, RES, VISF and APE might adversely affect the balance of the OPG/sRANKL system and thus potentially compromise the 
mechanism which compensates for bone remodelling disturbances. (Endokrynol Pol 2014; 65 (1): 33–39)
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Streszczenie
Wstęp: Celem pracy było wykazanie, czy u dziewcząt z jadłowstrętem psychicznym istnieje związek między LP, ADIPO, RES, VISF, 
APE-36 i APE-12 a markerami kostnymi, OPG i sRANKL.
Materiał i metody: U 86 dziewcząt z AN i 21 zdrowych w wieku 13–18 lat oceniono stężenia wybranych hormonów tkanki tłuszczowej, 
OC, CTx, OPG i sRANKL w surowicy metodą ELISA. 
Wyniki: U dziewcząt z AN wykazano istotne zmniejszenie masy ciała i BMI, obniżenie stężeń LP, RES, VISF, APE-36, APE-12 i markerów 
kostnych (OC i CTx) oraz wzrost stężenia ADIPO. Zmianom tym towarzyszył istotny wzrost stężeń OPG i sRANKL przy obniżonym 
wskaźniku OPG/sRANKL. Wykazano znamienną dodatnią korelację między BMI a LP, APE-36, CTx i wskaźnikiem OPG/sRANKL; OC 
a VISF; OPG a ADIPO; wskaźnikiem OPG/sRANKL a LP, APE-36, APE-12. Istotną, ujemną korelację stwierdzono między CTx, sRANKL 
a RES i APE-36; OPG a APE-36 i APE-12; wskaźnikiem OPG/sRANKL a ADIPO. Wykazano, że niezależnymi predykatorami są: dla OC — 
VISF, dla CTx i sRANKL — APE-36 i RES, dla OPG — APE-36 i ADIPO, a dla wskaźnika OPG/sRANKL — APE-36, LP i ADIPO.
Wnioski: Obserwowanym u dziewcząt z AN zmianom w stężeniach markerów kostnych, OPG, sRANKL i/lub wskaźniku OPG/sRANKL 
towarzyszą zmiany w stężeniach badanych hormonów tkanki tłuszczowej. Nieprawidłowości w powiązaniach między metabolizmem 
kostnym a LP, ADIPO, RES, VISF oraz APE u dziewcząt z AN mogą prowadzić do naruszenia równowagi układu OPG/sRANKL, co 
może skutkować upośledzeniem mechanizmu kompensującego zaburzenia w przebudowie kośćca. (Endokrynol Pol 2014; 65 (1): 33–39)
Słowa kluczowe: jadłowstręt psychiczny; dziewczęta; hormony tkanki tłuszczowej; metabolizm kostny; OPG; sRANKL 
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Introduction
Anorexia nervosa (AN) is an increasingly common 
eating disorder, a psychosomatic disease characterised 
by the pursuit of a ‘perfect’ silhouette through strictly 
limiting food intake, excessive exercise, self-provoked 
vomiting or engagement in other purging behaviours 
including the use of laxatives or diuretics. The disease 
leads to significant reduction of adipose tissue mass 
resulting in drastic slimness or even physical wasting 
(cachexia) [1, 2]. Patients with AN not only exhibit 
somatic and psychic complications resulting from dra-
matic weight loss but also, quite frequently, imbalance 
of hormones — also adipose tissue hormones [3–22]. 
It has been widely acknowledged that white adipose 
tissue, both subcutaneous and visceral, serves as a res-
ervoir of several active peptides, commonly referred 
to as adipokines, which have both local (autocrine and 
paracrine) and systemic (endocrine) actions [2]. It has 
been documented that adipokines are important regula-
tors of appetite and numerous metabolic, endocrine and 
immune functions of the organism. Several adipokines 
are mainly produced in subcutaneous white adipose 
tissue (leptin — LP, adiponectin — ADIPO) while oth-
ers (resistin — RES, visfatin —VISF) are predominantly 
secreted in the visceral adipose tissue. The least known 
of these hormones, apelin (APE), is expressed not only 
by adipocytes but has also been identified in vascular 
endothelium and the cells of several other tissues (lung, 
heart, brain) [2]. 
Osteoporosis is among the most commonly observed 
complications of AN. Osteoporosis has a multifactorial 
aetiology. Disturbances in the production, release and 
action of osteotropic agents, mainly hormones (includ-
ing adipose tissue hormones, i.e. LP and maybe also 
ADIPO, RES, VISF and APE), might lead to bone mineral 
density (BMD) decrease or, alternatively, absence of the 
BMD increase expected in adolescence [9, 10, 23] result-
ing from excessive bone resorption and inadequate 
formation of new bone. The system of receptor activator 
of nuclear factor-kB ligand/receptor activator of nuclear 
factor-kB/osteoprotegerin (RANKL/RANK/OPG) might 
play an important role in this process [24, 25]. According 
to a convergence hypothesis, the effect of several local 
and systemic agents on bone resorption consists of the 
regulation of OPG and/or RANKL expression [24, 25]. 
In vitro studies indicate that LP stimulates rat bone 
marrow stromal cells, thus enhancing differentiation to 
osteoblasts. It also causes an increase in the expression 
of bone matrix proteins mRNA; the effect depending on 
the dose and time of administration. Leptin enhances 
bone mineralisation [26–28] and inhibits osteoclast gen-
eration in cultures of murine bone marrow stromal cells 
[26–28], but does not affect mature osteoclast differen-
tiation [26]. It also increases OPG expression in stromal 
cells and osteoblasts [29, 30] and/or decreases the ex-
pression of RANKL [27, 30, 31]. Leptin acts to enhance 
in vitro differentiation of human bone marrow stem 
cells to osteoblasts, stimulates de novo collagen synthesis 
and bone matrix mineralisation [32–34] and inhibits 
adipogenesis [32]. It also inhibits osteclastogenesis in 
cultures of human peripheral blood mononuclear cells 
and spleen cells relative to OPG increase and RANKL 
decrease [32, 35]. Kanazawa et al. [36] demonstrated 
that ADIPO and AMP kinase activator stimulated the 
proliferation, differentiation, and mineralisation of 
MC3T3-E1 cells, while Luo et al. [37, 38] concluded 
that ADIPO stimulated human osteoblasts proliferation 
and differentiation and inhibited OPG expression in 
human osteoblasts via the MAPK signalling pathway. 
Thommesen et al. [39] found enhanced RES expression 
in murine osteoclast and osteoblasts precursor cells 
(RAW 264.7, MC3T3-E1) and in primary human bone 
marrow stem cells. The expression of resistin mRNA in 
RAW 264.7, increased during differentiation, seemed 
to be regulated through PKC- and PKA-dependent 
mechanisms. Recombinant resistin increased the num-
ber of differentiated osteoclasts and stimulated NF-kB 
promoter activity, indicating a significant role of this 
adipokine in osteoclastogenesis. Resistin also enhanced 
the proliferation of MC3T3-E1 cells in a PKA and PKC-
dependent manner, but only weakly interfered with 
genes known to be upregulated during differentiation 
of MC3T3-E1 into osteoblasts [39]. 
Other investigations have shown that VISF increases 
type I collagen production in human osteoblast cultures 
[40] while APE stimulates proliferation and suppresses 
apoptosis of mouse osteoblastic cell line MC3T3-E1 
[41]. The latter also has a protective effect on cultured 
rat bone marrow mesenchymal stem cells against 
apoptosis [42]. All these findings seem to suggest that 
the above mentioned adipokines might regulate bone 
remodelling, most probably through the cytokines of 
the RANKL/RANK/OPG system, mainly produced in 
osteoblasts and bone marrow stromal cells [24, 25, 27, 
30–32, 35, 37–39]. 
Several investigations involving healthy men and 
women have demonstrated a negative correlation be-
tween osteocalcin (OC), OPG and LP concentrations 
as well as between RANKL and ADIPO levels. OC 
concentrations were also positively correlated with 
ADIPO [43–46]. OPG concentrations were higher in 
a premenopausal than in a postmenopausal population 
[47–49]. The OPG/RANKL ratio correlated negatively 
with LP and positively with ADIPO independent of 
age, BMI and the time elapsed from menopause [45]. 
Investigations of relationships between serum LP, 
ADIPO, RES, VISF, APE and BMD have revealed that 
35
Endokrynologia Polska 2014; 65 (1)
PR
A
C
E 
O
RY
G
IN
A
LN
E
only ADIPO was an independent BMD predictor in 
postmenopausal women and middle-aged men [47–50]. 
Other authors found that both LP and ADIPO were 
determinants of BMD; RES was negatively correlated 
with BMD, but the correlation did not reach statistical 
significance (p = 0.062) [51].
Little data is available on the relationship between 
adipokines and bone status in patients with AN, and 
especially girls [3–10, 11, 23, 52–58]. The literature 
reports available are mainly concerned with the rela-
tion between LP, ADIPO and bone metabolism and/or 
BMD [8–10, 12, 23, 53, 54, 56–59]. Girls with AN exhibit 
considerable suppression of bone metabolism markers, 
i.e. bone-specific alkaline phosphatase, OC, C-terminal 
cross-linked telopeptide of type I collagen a chain (CTx), 
N-terminal cross-linked telopeptide of type-I collagen 
type I collagen a chain (NTx) and/or deoxypyridino-
line [9, 10, 21–23, 60, 61] correlating with a decrease 
in BMD and LP levels [9, 10, 23]. Several authors have 
determined OPG concentrations in girls with AN and 
found that, similar to young females with AN, the girls 
had elevated serum levels of this cytokine [4, 8, 21, 22, 
61]. Our earlier investigations revealed that serum 
sRANKL was increased while the OPG/sRANKL ratio 
was significantly decreased [21, 22, 61]. Similar results 
were obtained by Munoz-Calvo et al. [57]. However, no 
complex research studies have been carried out so far 
in girls with AN concerning the relationships between 
LP, ADIPO, RES, VISF, APE-36, APE-12 and bone me-
tabolism, OPG and its soluble ligand sRANKL.
Therefore, we decided to thoroughly investigate 
these relationships. Based on the scarce literature data 
available, we hypothesised that a BMD decrease or, 
alternatively, absence of the BMD increase expected 
in adolescence, might not only be caused by several 
already well-established factors, but also by the effect of 
changes in the concentrations of the above mentioned 
adipokines (or some of them) on the balance of the 
OPG/sRANKL system.
The aim of this study was: 1) to determine whether 
girls with AN exhibited any relationships between LP, 
ADIPO, RES, VISF, APE-36, APE-12 and bone metabo-
lism (as assessed based on serum OC and CTx levels); 
and 2) to establish whether OPG and its soluble ligand 
sRANKL might affect such relationships.
Material and methods
The study involved 86 girls aged 13 to 18 years, hospi-
talised at the Paediatric Endocrinology Division of the 
Paediatric Department in Zabrze Medical University of 
Silesia in Katowice (Poland), who, following paediatric 
examination and psychiatric consultation, had been di-
agnosed with anorexia nervosa according to Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV) 
published by the American Psychiatric Association in 
1994. The average disease duration was 12.1 months 
(range 3–36 months). All examined girls were at Tanner 
puberty stages IV and V. They had normal liver and 
kidney functions; no severe somatic complications or 
psychiatric disorders were observed. On recruitment, 
no patients were taking medications known to affect 
the nutritional and bone status including calcium or vi-
tamin D supplements. During hospitalisation, patients 
were placed at bed rest, which is the standard care. 
The control group comprised 21 age-matched healthy 
regularly menstruating adolescent females with no en-
docrine or other disorders that might possibly influence 
adipose and bone tissue metabolism. During the three-
month period before the study, the control participants 
did not take calcium or vitamin D supplements. 
The height (stadiometer) and body mass (electronic 
scale) of all participants were measured, and their body 
mass index (BMI) calculated. Blood samples (8 mL) for 
determination of LP, ADIPO, RES, VISF, APE-36, APE-
12, OC and CTx as well as OPG and sRANKL were 
collected between 08.00 and 09.00 hours following 
a 12-hour fast. Centrifuged serum was frozen and stored 
at –75°C until assayed for the above mentioned adipose 
tissue hormones, bone markers, OPG and sRANKL.
Determinations of the concentrations of adipose 
tissue hormones, OC, CTx, OPG and sRANKL were 
performed by ELISA using the following kits: LP and 
ADIPO (Bio-Vendor, LLC, USA), RES (Mediagnost, Ger-
many), VISF, APE-36 and APE-12 (Phoenix Pharmaceu-
ticals Inc., Burlingame, CA, USA), OC (DSL Inc., USA), 
CTx (Nornic Bioscience Diagnostics A/S, Denmark), 
OPG and sRANKL (Biomedica, Austria). The respective 
sensitivity, intra- and inter-assay errors were: 0.5 ng/mL, 
7.5 and 9.2% for LP; 0.7 ng/mL, 7 and 8.2% for ADIPO; 
0.3 ng/mL, 5 and 6.8% for RES; 0.55 ng/mL, 5 and 14% 
for VISF; 0.09 ng/mL, 5 and 14% for APE-36; 0.07 ng/mL, 
5 and 14% for APE-12; 0.05 μmol/L, 5.8 and 7.3% for 
OC; 0.08 nmol/L, 5.2 and 6.7% for CTx; 0.14 pmol/L, 
7 and 7.5% for OPG; 0.04 pmol/L, 5 and 7% for sRANKL. 
The database was prepared using Excel 2000 (Mi-
crosoft Corporation). Statistical analysis was carried 
out with Statistica 10 for Windows (StatSoft Inc., USA). 
The t-test was used to determine the significance of in-
tergroup differences (normal distribution of variables). 
In the case of non-normal distribution, the significance 
was tested using the Mann-Whitney U test. The rela-
tionships between LP, ADIPO, RES, VISF, APE-36, APE-
12, OC, CTx, OPG, sRANKL and the OPG/sRANKL ratio 
were analysed by Spearman’s correlation. The level of 
significance was set at p £ 0.05.
Stepwise regression was used to determine whether 
any, and if so which, of the adipose tissue hormones 
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under investigation were independent predictors of 
bone markers (OC and CTx), cytokines of the RANKL/ 
/RANK/OPG system and the OPG/sRANKL ratio (model 
entry was set at p = 0.05, and model exit at p = 0.05). 
The study was approved by the Regional Bio ethics 
Committee of the Medical University of Silesia in Ka-
towice (KNW/0022/KB1/105/09). 
Results
Our female adolescents with AN showed a significant 
reduction in body mass and BMI compared to the 
control group. A significant decrease in mean serum 
LP, RES, VISF, APE-36 and APE-12 concentrations, and 
a significant increase in mean serum ADIPO, were also 
found. These changes were associated with a significant 
decrease in mean OC and CTx levels, marked increases 
in OPG and sRANKL, and a significant decrease in the 
OPG/sRANKL ratio compared to the controls (Table I).
Girls with AN exhibited significant positive correla-
tions between BMI and LP, APE-36, CTx and the OPG/ 
/sRANKL ratio (Table II). CTx and sRANKL were nega-
tively and significantly correlated with RES and APE-36; 
OPG was negatively and significantly correlated with 
APE-36 and APE-12, while the OPG/sRANKL ratio cor-
related negatively and significantly with ADIPO. Posi-
tive and significant correlations were observed between 
OC and VIFS; OPG and ADIPO as well as between the 
OPG/sRANKL and LP, APE-36 and APE-12 (Table III).
VISF was shown to be an independent predictor 
of OC (R2 = 0.071, p = 0.020). APE-36 and RES turned 
out to be independent predictors of CTx and sRANKL 
(R2 = 0.062, p = 0.015 and R2 = 0.082, p = 0.041, respec-
tively). APE-36 and ADIPO were independent predic-
tors of OPG (R2 = 0.173, p = 0.008), while APE-36, LP 
and ADIPO were independent predictors of the OPG/ 
/sRANKL ratio (R2 = 0.264, p = 0.005).
Discussion
Girls with AN suffer from a considerable decrease of 
bone mass [8–10, 12, 23, 54, 60, 62, 63] and bone me-
tabolism disturbances [3–11, 21–23, 53, 54, 57, 61, 62]. 
The majority of authors emphasise the suppression of 
bone formation and bone resorption markers in these 
patients which appears correlated with BMI and/or 
BMD [4, 5, 12, 21, 22, 52, 53, 61, 63]. 
Our results are consistent with these findings. 
However, only few of the above mentioned authors 
determined OPG concentrations in girls with AN [4, 8, 
21, 22, 57, 61]. It was found that, similar to young females 
with AN [64], girls with AN exhibited a considerable 
increase of serum OPG. Misra et al. [4] suggested that 
decreased levels of bone resorption markers in girls 
with AN might indicate a suppressive effect of elevated 
serum OPG on osteoclast activity and differentiation. 
However, it should be emphasised that Misra et al. [4] 
did not investigate the levels of RANKL and the values 
of the OPG/sRANKL ratio. Munoz-Calvo et al. [57] and 
Ostrowska et al. [21, 22, 61] determined serum OPG and 
sRANKL in female adolescents with AN and revealed 
significant suppression of the OPG/sRANKL ratio in 
patients with normal [57] or significantly increased OPG 
levels [21, 22, 61] and significantly increased sRANKL 
[21, 22, 57, 61].
Low values of the OPG/sRANKL ratio with a paral-
lel increase in serum OPG and sRANKL demonstrated 
in our previous studies [21, 22, 61] and confirmed in 
the present investigations, along with some degree of 
desynchronisation of the relationships between the 
Table I. Mean values of age, height, body mass, body mass 
index (BMI), mean serum levels of chosen adipose tissue 
hormones, osteocalcin (OC), collagen type I crosslinked 
carboxyterminal telopeptide (CTx), osteoprotegerin (OPG), 
soluble receptor activator of nuclear factor-kB ligand 
(sRANKL) and OPG/sRANKL ratio values in girls with 
anorexia nervosa and the control group 
Tabela I. Średni wiek, masa ciała, wskaźnik masy ciała 
(BMI), średnie stężenia wybranych hormonów tkanki 
tłuszczowej, osteokalcyny (OC), karboksyterminalnego 
usieciowanego telopeptydu łańcucha a1 kolagenu typu I 
(CTx), osteoprotegeryny (OPG), rozpuszczalnego ligandu 
receptora aktywatora czynnika jądrowego-kB (sRANKL) 
i wartości wskaźnika OPG/sRANKL u dziewcząt z jadło-
wstrętem psychicznym i w grupie kontrolnej
Variables Groups
Anorexia  
nervosa 
(n = 86)
Control  
group 
(n = 21)
Age (years) 15.45 ± 1.32 15.35 ± 1.72
Height [m] 1.62 ± 0.04 1.63 ± 0.05
Body mass [kg] 39.50 ± 5.24* 52.33 ± 5.56
BMI [kg/m2] 14.79 ± 1.62* 19.71 ± 1.26
Leptin (LP) [ng/mL] 4.96 ± 1.01* 14.62 ±1.13
Adiponectin (ADIPO) [μg/mL] 43.67 ± 5.21* 24.35 ± 2.52
Resistin (RES) [ng/mL] 2.86 ± 0.45* 4.20 ± 0.39
Visfatin (VISF) [ng/mL] 1.00 ± 0.26* 2.49 ± 0.38
Apelin-36 (APE-36) [pg/mL] 98.11 ± 8.51* 129.15 ± 14.32
Apelin-12 (APE-12) [pg/mL] 96.81 ± 8.90* 130.02 ± 16.61
OC [μmol/L] 0.91 ± 20.80* 3.12 ± 1.5
CTx [nmol/L] 7.22 ± 0.92* 7.99 ± 0.91
OPG [pmol/L] 5.21 ± 0.78* 3.41 ± 0.69
sRANKL [pmol/L] 0.45 ± 0.14* 0.28 ± 0.12
OPG/sRANKL ratio 9.72 ± 0.83* 13.98 ± 1.08
*p £ 0.05 v. control group
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above mentioned cytokines and bone markers [21, 22], 
seem to suggest that girls with AN might exhibit 
a compromise in the mechanism which controls bone 
remodelling and/or mechanism compensating for 
enhanced bone turnover. Munoz-Calvo et al. [57] also 
reported a significant decrease in the OPG/RANKL 
ratio correlated with an increase in serum RANKL as 
well as a positive and significant correlation between 
the OPG/RANKL ratio and BMD. However, they did 
not observe a significant OPG increase in serum of girls 
with AN, or any relationships between OPG, RANKL 
and BMD. According to Munoz-Calvo et al. [57], the 
decrease in the OPG/RANKL ratio in girls with AN 
only partly explains increased bone loss observed 
in these patients. It has been well established that 
17b-oestradiol is the major regulator of bone metabolism 
and BMD in both women and girls suffering from AN. 
However, it is also known that cytokines under inves-
tigation, in particular OPG, are modified not only by 
17b-oestradiol, but also by other hormones, cytokines 
and mesenchymal transcription factors [24, 25] whose 
effect on cytokines concentrations is opposite to that 
of 17b-oestradiol. Therefore, the ultimate effect of all 
these actions is difficult to predict.
In vitro and in vivo studies have indicated that, apart 
from several well-known hormones, bone metabolism 
may also be modified by some adipose tissue hormones 
[8, 26–28, 30–34, 40, 42–50, 56–58, 65–68]. It has also been 
Table II. Correlation between body mass index (BMI), 
chosen adipose tissue hormones, osteocalcin (OC), collagen 
type I crosslinked carboxyterminal telopeptide (CTx), 
osteoprotegerin (OPG), soluble receptor activator of nuclear 
factor-kB ligand (sRANKL) and OPG/sRANKL ratio in girls 
with anorexia nervosa (n = 86)
Tabela II. Korelacja między wskaźnikiem masy ciała (BMI), 
wybranymi hormonami tkanki tłuszczowej, osteokalcyną 
(OC), karboksyterminalnym usieciowanym telopeptydem 
łańcucha a1 kolagenu typu I (CTx), osteoprotegeryną (OPG), 
rozpuszczalnym ligandem receptora aktywatora czynnika 
jądrowego-kB (sRANKL) i wartościami wskaźnika OPG/ 
/sRANKL u dziewcząt z jadłowstrętem psychicznym (n = 86)
Variables Values of correlation 
coefficients — R 
BMI [kg/m2] Leptin (LP) [ng/mL] 0.271*
Adiponectin (ADIPO) [μg/mL] NS
Resistin (RES) [ng/mL] NS
Visfatin (VISF) [ng/mL] NS
Apelin-36 (APE-36) [pg/mL] 0.214*
Apelin-12 (APE-12) [pg/mL] NS
OC [μmol/L] NS
CTx [nmol/L] 0.315*
OPG [pmol/L] NS
sRANKL [pmol/L] NS
OPG/sRANKL ratio 0.268*
*p £ 0.05 — statistically significant values of correlation coefficients
Table III. Correlationa between chosen adipose tissue hormones, osteocalcin (OC), collagen type I crosslinked carboxyterminal 
telopeptide (CTx), osteoprotegerin (OPG), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and OPG/sRANKL 
ratio in girls with anorexia nervosa (n = 86)
Tabela III. Korelacjaa między wybranymi hormonami tkanki tłuszczowej, osteokalcyną (OC), karboksyterminalnym 
usieciowanym telopeptydem łańcucha a1 kolagenu typu I (CTx), osteoprotegeryną (OPG), rozpuszczalnym ligandem receptora 
aktywatora czynnika jądrowego-kB (sRANKL) i wartościami wskaźnika OPG/sRANKL u dziewcząt z jadłowstrętem 
psychicznym (n = 86)
Variables Bone markers Cytokines of RANKL/RANK/OPG 
system
OPG/sRANKL ratio
OC [μmol/L] CTx [nmol/L] OPG [pmol/L] sRANKL [pmol/L]
Leptin (LP) [ng/mL] NS NS NS NS 0.252*
Adiponectin (ADIPO) [μg/mL] NS NS 0.234* NS –0.245*
Resistin (RES) [ng/mL] NS –0.215* NS –0.236* NS
Visfatin (VISF) [ng/mL] 0.266* NS NS NS NS
Apelin-36 (APE-36) [pg/mL] NS –0.212* –0.269* –0.240* 0.443*
Apelin-12 (APE-12) [pg/mL] NS NS –0.361* NS 0.225*
Stepwise regression modelb
 
R2
p
VISF
 
0.071
0.020
APE-36  
RES
0.062
0.015
APE-36  
ADIPO
0.173
0.008
APE-36  
RES
0.082
0.041
APE-36 LP 
ADIPO
0.264
0.005
aDisplayed value represents the model variance explained by these parameters; bParameters entering the stepwise regression model; NS — non significant values of 
correlation coefficients (p > 0.05); *p £ 0.05 — statistically significant values of correlation coefficients
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suggested that the latter might regulate bone remodel-
ling both directly and indirectly, i.e. via affecting OPG 
and/or RANKL expression [24, 25, 31, 38, 45, 56]. 
The findings concerning serum LP, ADIPO, RES and 
VISF concentrations in patients with AN, and especially 
in adolescent females suffering from the disease, are 
not unanimous. Our previous [12, 13–19] and present 
studies in girls with AN revealed suppression of LP, 
RES and VISF levels while ADIPO concentrations were 
increased. The results of other authors’ investigations 
are similar to ours [5–8, 53–56, 60, 66, 69–73]. Only a few 
of these studies have also assessed the relationships 
between the above mentioned adipose tissue hormones 
(or some of them) and BMD and/or bone metabolism in 
patients with AN [3–8, 53–55, 56, 66]. The same regards 
the relationships between LP and/or ADIPO, RES, VISF 
and bone status with a focus on possible interaction of 
cytokines of the RANKL/RANK/OPG system [4, 8, 55, 56, 
66]. Several findings [4, 8, 56, 66] indicate a relationship 
between LP and/or ADIPO and RES and bone status. 
In vitro studies [4, 31, 38, 45] seem to suggest that the 
above mentioned adipokines, and especially LP and 
ADIPO, modify bone metabolism, most probably via 
their effect on RANKL and/or OPG expression. 
Our investigations of girls with AN demonstrated 
that serum LP, RES, VISF, APE-36 and APE-12 sup-
pression and ADIPO elevation were associated with 
a decrease in bone markers concentrations, low values 
of the OPG/sRANKL ratio with a parallel increase in 
serum OPG and sRANKL. CTx and sRANKL correlated 
negatively and significantly with RES and APE-36; OPG 
correlated negatively and significantly with APE-36 and 
APE-12, while the OPG/sRANKL ratio was negatively 
and significantly correlated with ADIPO. However, 
significant positive correlations were revealed between 
OC and VISF; OPG and ADIPO; the OPG/sRANKL 
ratio and LP, APE-36 and APE-12. Our findings confirm 
in vivo results of other authors [3–11, 23, 52, 53–59, 66], 
who hypothesised a relationship between bone status 
and some of the above mentioned adipose tissue hor-
mones (i.e. LP, RES and ADIPO) in adolescent females 
with AN. We would also like to emphasise the role of 
VISF and APE in the regulation of bone remodelling in 
these patients. In vitro investigations into the effect of 
LP [26, 27, 31–35, 74], ADIPO [36–38, 74], RES [39], VISF 
[40] and APE [41, 42] on bone tissue cells are consistent 
with the above hypothesis. Stepwise regression analysis 
carried out in our patients revealed that VISF was an 
independent predictor of OC. APE-36 and RES turned 
out to be independent predictors of CTx and sRANKL; 
APE-36 and ADIPO were independent predictors of 
OPG, while APE-36, LP and ADIPO were independ-
ent predictors of the OPG/sRANKL ratio. Thus, it can 
be hypothesised that decreased LP, RES, VISF and APE 
production and increased ADIPO secretion observed 
in girls with AN might have an adverse effect on bone 
tissue, probably via a shift in the OPG/sRANKL ratio 
toward a functional excess of sRANKL.
Conclusions
Changes in bone markers, OPG, sRANKL and/or the 
OPG/sRANKL ratio exhibited by girls with anorexia 
nervosa have been found to be associated with changes 
in the levels of the selected adipose tissue hormones.
 Abnormal relationships between bone metabolism 
and leptin, adiponectin, resistin, visfatin and apelin 
observed in girls suffering from anorexia nervosa might 
adversely affect the balance of the OPG/sRANKL sys-
tem and potentially compromise the mechanism which 
compensates for bone remodelling disturbances.
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